For example, in prostate cancer, osteosarcoma and PDAC [54, 55], inhibition of TACC3 restrains growth, proliferation or migration of cancer cells, while in breast cancer it leads to an opposite effect as is observed by Huo et al. Secondly, in various tumor types, the dominant molecular mechanism of TACC3 may be different, which may lead to opposite phenotypes. Here, TACC3 is linked to cancer.